文献速递妇科

二甲双胍与他汀类药物在2型糖尿病女性上皮性卵巢癌发病中的作用:队列与巢式病例对照研究

The role of metformin and statins in the incidence of epithelial ovarian cancer in type 2 diabetes: a cohort and nested case-control study.
PubMed 文献 · BJOG · 2018-03-12

基于芬兰全国登记数据库的回顾性队列与巢式病例对照研究,纳入137 643例40岁以上2型糖尿病女性,随访期间303例发生卵巢癌;二甲双胍(HR 1.02,95%CI 0.72-1.45)与他汀(HR 0.99,95%CI 0.78-1.25)均与卵巢癌发病率无关联,巢式病例对照分析结果基本一致。

要点

  • 二甲双胍使用与卵巢癌发病无关联(HR 1.02,95%CI 0.72-1.45)。
  • 他汀使用与卵巢癌发病无关联(HR 0.99,95%CI 0.78-1.25)。
  • 巢式病例对照分析结果与全队列分析基本一致。

核心结论

  • 未发现二甲双胍或他汀使用与2型糖尿病女性卵巢癌发病率存在关联的证据。

研究设计与样本

  • 回顾性队列研究和巢式病例对照研究,数据来自芬兰全国登记数据库(FinDM)。
  • 队列纳入1996-2011年芬兰诊断的137 643例40岁以上2型糖尿病女性。
  • 全队列分析采用泊松回归估计风险比(HR),巢式病例对照分析按每例卵巢癌匹配20例对照,采用条件逻辑回归估计HR,并调整年龄和2型糖尿病病程。

主要发现

  • 随访期间共303例女性诊断为卵巢癌。
  • 与其他口服降糖药相比,二甲双胍与卵巢癌发病率无关联(HR 1.02,95%CI 0.72-1.45)。
  • 他汀与卵巢癌发病率无关联(HR 0.99,95%CI 0.78-1.25)。
  • 巢式病例对照分析结果与全队列分析基本相似。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To obtain evidence of the effects of metformin and statins on the incidence of ovarian cancer in women with type 2 diabetes (T2D). DESIGN: A retrospective cohort study and nested case-control study. SETTING: The data were obtained from a diabetes database (FinDM) combining information from several nationwide registers. POPULATION: A cohort of 137 643 women over 40 years old and diagnosed with T2D during 1996-2011 in Finland. METHODS: In full cohort analysis Poisson regression was used to estimate the hazard ratios (HR) in relation to ever use of metformin, insulin other oral anti-diabetic medication or statins. In the nested case-control analysis 20 controls were matched to each case of ovarian cancer. Conditional logistic regression was used to estimate HRs in relation to medication use and cumulative use of different medications. The estimates were adjusted for age and duration of T2D. MAIN OUTCOME MEASURE: Incidence of ovarian cancer. RESULTS: In all, 303 women were diagnosed with ovarian cancer during the follow up. Compared with other forms of oral anti-diabetic medication, metformin (HR 1.02, 95% CI: 0.72-1.45) was not found to be associated with the incidence of ovarian cancer. Neither was there evidence for statins to affect the incidence (HR 0.99, 95% CI: 0.78-1.25). In nested case-control analysis the results were essentially similar. CONCLUSIONS: No evidence of an association between the use of metformin or statins and the incidence of ovarian cancer in women with T2D was found. TWEETABLE ABSTRACT: No evidence found for metformin or statins reducing the incidence of ovarian cancer.

来源:BJOG,查看原文。版权归原作者所有。

引用

  1. Urpilainen E, Marttila M, Hautakoski A, et al. The role of metformin and statins in the incidence of epithelial ovarian cancer in type 2 diabetes: a cohort and nested case-control study. BJOG. 2018. PMID: 29412502. doi:10.1111/1471-0528.15151

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。